At the Aids 2026 conference, Brazilian advocates said health systems need to be more independent from foreign funding ...

CRISPR therapy EBT-101 targeted HIV DNA inside living humans for the first time, showing strong safety results but failing to prevent viral rebound after ART stopped.

If you're a Black, 34-year-old South African woman living with HIV, antiretroviral (ARV) treatment options have likely been ...

Figure 2 from the PURPOSE-1 trial changed the world. Between gray and red bars representing the study’s background HIV incidence and the arms randomized to receive oral pre-exposure prophylaxis (PrEP) ...

A once-weekly HIV pill combining the antiretroviral drugs islatravir and lenacapavir is as effective as a widely used once-daily regimen, according to an international study. More than 93% of ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...

Widespread distrust of our public health system is reviving long-debunked ideas on HIV and AIDS—and energizing a broad movement that questions the foundations of disease prevention. Several million ...

Researchers at the UC Davis School of Medicine have identified a naturally occurring metabolite that repairs gut damage ...

Cambodia is the first country in the Asia–Pacific to reach the 95–95–95 targets. There is hope that other countries might ...

UNAIDS Brazil and Grindr for Equality—Grindr’s global social impact initiative, committed to advancing health and human ...

Aging with HIV comes with an increased risk of other health problems. Failing to get adequate care could undermine fighting the virus. (Story aired on Weekend Edition Saturday on June 15, 2024.) ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...